Nuvectis Pharma, Inc. · NASDAQ:NVCT

Nuvectis Pharma — Investor Presentation (August 2025)

26 slides from Nuvectis Pharma's investor presentation, August 2025

  1. Slide 1: Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology August 2025 (NASDAQ: NVCT)

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Nuvectis Pharma, Inc. This presentation contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in

  3. Slide 3: Nuvectis Pharma – Key Highlights

    Nuvectis Pharma – Key Highlights Our Approach to  Select and acquire novel, rationally-designed drug candidates Precision Medicine  Focus on drug development for serious conditions of unmet need in oncology NXP800  Phase 1a dose escalation and DDI studies completed NXP900  Potential indications:

  4. Slide 4: Management Team

    Management Team Track record of success Ron Bentsur Enrique Poradosu, PhD Shay Shemesh Chairman & Chief Executive Officer Chief Scientific & Business Officer Chief Development & Operations Officer Jelmyto® (mitomycin) NuvectisPharma, Inc. 4

  5. Slide 5: About NXP900

    € About NXP900

  6. Slide 6: NXP900 Key Highlights

    NXP900 Key Highlights  Discovered at the University of Edinburgh, Scotland Precision Medicine Approach  A potent, novel, small molecule inhibitor of YES1/SRC signaling Differentiated  Highly selective Features  Unique mechanism of action - Complete shut-down of the SRC pathway by scaffold and ca

  7. Slide 7: NXP900 Kinome Profiling Demonstrates High Selectivity

    NXP900 Kinome Profiling Demonstrates High Selectivity NXP900 Dasatinib Note: Dasatinib data from Remsing Rix et al., Leukemia 23, 477–485 (2009), NXP900 data from AACR 2022. NuvectisPharma, Inc. 7

  8. Slide 8: NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family

    NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family Differentiated vs. other multi-kinase inhibitors that only achieve partial SRC pathway shut down SRC-NXP900 co-crystal structure SRC-dasatinib co-crystal Binding to YAP Binding to FAK, CAS, paxillin, etc. Dasat

  9. Slide 9: NXP900 Clinical Progress

    NXP900 Clinical Progress  Phase 1a dose escalation study completed (7 dose cohorts: 20 – 300 mg/day)  DLT dose level not identified  Starting dose selected for Part B: 200 mg/day  Combination-enabling DDI study completed NuvectisPharma, Inc. 9

  10. Slide 10: NXP900-101 Clinical Dose Prediction

    NXP900-101 Clinical Dose Prediction In Vitro NXP900 simulated human dose between 40 mg QD and 200 mg QD provided steady state Ctrough concentration of approximately Dose Total NX900 Ctrough,ss 26 nM to 130 nM. (mg QD) (ng/mL) These values represent GI50 multipliers of approximately 6-28 for the most

  11. Slide 11: NXP900-101 Clinical Dose Prediction

    NXP900-101 Clinical Dose Prediction Mouse PK Predictions In Vivo Dose AUCtau  Simulated steady state exposure in humans (at (mg/kg QD) (ng/mL.h) doses between 20 to 350 mg QD), was compared 25 2112 to extrapolated mouse PK parameters after 40 3379 multiple oral doses of 25 mg/kg or 40 mg/kg. Human

  12. Slide 12: NXP900-101: Preliminary Summary of TEAEs (N=33)

    NXP900-101: Preliminary Summary of TEAEs (N=33) Event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total Diarrhea 8 (24) 6 (18) 1 (3) 0 (0) 0 (0) 15 (45) Fatigue 3 (9) 9 (27) 2 (6) 0 (0) 0 (0) 14 (42) Nausea 8 (24) 4 (12) 0 (0) 0 (0) 0 (0) 12 (36) Decreased appetite 2 (6) 8 (24) 0 (0) 0 (0) 0 (0) 10 (30)

  13. Slide 13: Pharmacodynamic Activity in Phase 1

    Pharmacodynamic Activity in Phase 1 Treatment with NXP900 results in robust and consistent inhibition of SRC autophosphorylation  NXP900 achieves approx. 90% inhibition of SRC autophosphorylation (pSRC) after a single dose at doses ≥150 mg/day  DLT dose level not identified Cycle 1 Day 1 Cycle 2 D

  14. Slide 14: Clinical DDI Study: Topline Results

    Clinical DDI Study: Topline Results  Study Population: 14 healthy volunteers  Key Pharmacokinetics Result (preliminary):  NXP900 increased the concentration of Midazolam, a known CYP3A sensitive substrate, by < 2-fold, classifying it as a weak inhibitor of CYP3A  NXP900 increased the concentrati

  15. Slide 15: Validation of SRC as a Clinical Target in NSCLC

    Validation of SRC as a Clinical Target in NSCLC Saracatinib case study  Saracatinib was developed as a target-specific SRC inhibitor  Saracatinib was clinically active at a dose of 175 mg/day (the RP2D) in a clinical study in patients with NSCLC (not enriched for specific genetic alterations) • 2

  16. Slide 16: Single Agent Strategy Rationale

    Single Agent Strategy Rationale Hippo pathway mutations and YES1 gene amplification are associated with sensitivity to NXP900 Mechanistic Rationale Preclinical POC In Vivo HCC95 Xenograft Model SW900 Xenograft Model Lung Squamous, YES1 amplification Lung Squamous, FAT1 mutation Created with BioRende

  17. Slide 17: Phase 1b Expansion: Single Agent

    Phase 1b Expansion: Single Agent Tumors of different types harbor relevant molecular alterations supported by in vivo data Tumor Types Key Molecular Alterations  NSCLC, Kidney, Mesothelioma  YES1 and YAP1 amplifications  Other solid tumors  NF2 and FAT1 mutations NuvectisPharma, Inc. 17

  18. Slide 18: NXP900 Single Agent: Market Opportunity in Key Subsets

    NXP900 Single Agent: Market Opportunity in Key Subsets  Potent activity demonstrated in vivo • Models of YES1 amplifications (esophageal and lung squamous) • Models of FAT1 mutations (lung and head & neck squamous) NuvectisPharma, Inc. 18

  19. Slide 19: NXP900 Combination Opportunity

    NXP900 Combination Opportunity Targeting resistance to ALK/EGFR TKIs in NSCLC  ALK and EGFR targeted agents have demonstrated potent and durable activity in NSCLC  However, emergence of resistance to ALK and EGFR targeting drugs is inevitable  SRC, YES1 and YAP1 activation have been extensively v

  20. Slide 20: About NXP800

    € About NXP800

  21. Slide 21: Final Data Update from the Phase 1b in Platinum-resistant ARID1a-mutated ovarian cancer

    Final Data Update from the Phase 1b in Platinum- resistant ARID1a-mutated ovarian cancer  Final data release for the 75 mg/day group included 2 PR’s (unconfirmed) and 3 SD’s out of 13 patients  Thrombocytopenia well controlled with intermittent dosing. the most common treatment emergent adverse ev

  22. Slide 22: NXP800 Potential Opportunity in Multiple Cancers

    NXP800 Potential Opportunity in Multiple Cancers ARID1a is an important mutation that can be used as a patient selection strategy a Estimated Incidence ARID1a mutation Estimated Number of Patients Indication (US) prevalence with ARID1a protein loss (US) Ovarian Cancer 4,350 52.9% 2,300 (Clear Cell a

  23. Slide 23: Financial Highlights and Upcoming Milestones

    Financial Highlights and Upcoming Milestones Selected Financial Highlights Expected 2025 Milestones Financial Information Program Milestone Ticker NVCT  Phase 1a and DDI studies completed update $39 million pro forma as of June 30, Cash Dose escalation results from first-in-human study 2025 NXP900

  24. Slide 24: Research Coverage

    Research Coverage Ladenburg Thalman Aydin Huseynov Roth-MKM Jonathan Aschoff Lucid Capital Markets Christopher Liu Yale Jen Laidlaw & Company Maxim Group Naz Rahman H.C. Wainwright Joe Pantginis NuvectisPharma, Inc. 24

  25. Slide 25: Nuvectis Investment Highlights

    Nuvectis Investment Highlights Precision medicine pipeline for serious conditions of unmet medical need in oncology  Commencement of the Phase 1b program for NXP900 2025 Milestones  Phase 1a and DDI studies presentations at medical and scientific conferences NXP800  Highly selective compound, dif

  26. Slide 26: Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology August 2025 (NASDAQ: NVCT)

Nuvectis Pharma — Investor Presentation (August 2025) on 6ix